依达拉奉早期应用于急性缺血性卒中的临床分析

目的观察依达拉奉治疗急性缺血性卒中的疗效。方法选择82例发病时间在6～72 h的急性缺血性卒中患者,随机分为治疗组42例,对照组40例。治疗组在基础治疗的基础上加用依达拉奉30mg加入0.9%氯化钠注射液100 ml静脉滴注,每天2次,连用14 d;对照组仅给予基础治疗和0.9%氯化钠注射液100ml静脉滴注,每天2次,连用14 d。比较两组治疗前后的患者临床神经功能缺损程度评分和临床疗效。结果治疗前两组临床神经功能缺损评分无明显差异(21.23±5.64分vs 20.23±5.14分,P0.05)。治疗14 d后,治疗组评分低于对照组(9.60±2.50 vs 12.10+2.21,P=0.027)。治疗组临床疗效总有效率为92.8%,对照组为72.5%,差异有统计学意义(P=0.016)。结论依达拉奉治疗急性缺血性卒中有显著疗效。

Clinical Analysis of Applying Edaravone Early in Acute Cerebral Infarction

Objective To observe the effects ofedaravone on acute cerebral infarction（ACl）. Methods Eighty-two acute cerebral infarction patients who were admitted to hospital 6-72h after onset were randomly divided into treatment group and control group by half. The treatment group was given intravenous edaravone by drops（30 mg edaravone were added to 100 ml physiological saline）, twice a day for 14 days. The control group was given the same treatments except edaravone. Conditions of both groups before and after the treatment were evaluated by clinical neurological deficit scores and were compared with each other. Results Fourteen days after treatment, clinical neurological deficit scores of the treatment group were significant lower than that of the control group（P=0.027）, 14d after treatment, both obvious effects and effects rates of the treatment group were significant higher than that of the control group P=0.016）. Conclusion Edaravone is effective on ACI without any serious adverse reaction being observed.